VBI Vaccines (NASDAQ:VBIV) Research Coverage Started at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of VBI Vaccines (NASDAQ:VBIV) in a research report issued on Saturday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

VBI Vaccines Price Performance

Shares of VBIV stock opened at $0.59 on Friday. VBI Vaccines has a one year low of $0.45 and a one year high of $3.47. The company’s fifty day moving average price is $0.61 and its 200-day moving average price is $0.61. The company has a market capitalization of $16.92 million, a price-to-earnings ratio of -0.05 and a beta of 1.90.

VBI Vaccines Company Profile

VBI Vaccines Inc, a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.